ArticleStem cells translational medicine2025
Transplantation of mesenchymal stromal cell-derived mitochondria alleviates endothelial dysfunction in pre-clinical models of acute respiratory distress syndrome.
Article in Stem cells translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Mitochondrial Transplantation from Bone Marrow Mesenchymal Stromal Cells Combined with Sildenafil Attenuated Vascular Remodeling and Improved Right Ventricular Dysfunction in Experimental Pulmonary Arterial Hypertension.International journal of molecular sciences · 2026Article
- Lipid droplet-mitochondria contact sites as druggable spatial-pharmacology targets in respiratory disease: cross-cell-type mechanisms and translational strategies.Frontiers in cell and developmental biology · 2026Review
- Targeting mitochondria for the treatment of neurodegenerative diseases.Frontiers in neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundPulmonary endothelial dysfunction with increased capillary permeability is a key aspect in the pathogenesis of acute respiratory distress syndrome (ARDS). It has been demonstrated that mesenchymal stromal cells (MSC) can modulate host cells through mitochondrial transfer. Although mitochondrial transplantation is a promising treatment strategy for conditions underpinned by mitochondrial dysfunction, its therapeutic potential in ARDS has not been sufficiently investigated. Herein, we tested the potential of MSC mitochondrial transplantation to restore functionality of the pulmonary endothelium in pre-clinical models of ARDS.
methodsMitochondria (mt) derived from human bone-marrow MSC were isolated and immediately used for transplantation to primary human pulmonary microvascular endothelial cells (HPMEC) in the presence of Escherichia coli lipopolysaccharide (LPS) or plasma samples from ARDS patients classified into hypo- and hyper-inflammatory phenotypes. Mitochondrial function, inflammatory status, and barrier integrity of HPMEC were assessed at 24 h. LPS- challenged mice were treated with MSC-mt intravenously, and the severity of lung injury and inflammatory response were evaluated.
resultsExposure to LPS or ARDS plasma induced endothelial hyperpermeability associated with mitochondrial dysfunction. MSC-mt were readily internalized by HPMEC without cytotoxicity or inflammatory response, mitigating mitochondrial dysfunction and restoring barrier integrity. In vivo, administration of MSC-mt alleviated lung injury, reduced inflammatory cell infiltration in the alveoli and increased VE-cadherin mRNA levels in the lung tissue, indicating restoration of the alveolar-capillary barrier integrity.
conclusionThis study demonstrated MSC mitochondrial transplantation as a promising therapeutic approach for treatment of endothelial dysfunction in the context of acute inflammation. Further exploration of mitochondrial transplantation in ARDS is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.